Abstract
purpose. To examine the detection rates, specificity, and agreement between visual field (VF) progression and Heidelberg Retina Tomograph (HRT; Heidelberg Engineering, GmbH, Heidelberg, Germany) rim area (RA) progression in subjects with ocular hypertension (OHT).
methods. One hundred ninety-eight OHT and 21 control subjects were examined prospectively (1994–2001) with regular Humphrey VF (Carl Zeiss Meditec, Inc., Dublin, CA) and HRT testing. Point-wise linear regression (PLR) of sensitivity/time was used to assess VF progression, using standard and three-omitting (less stringent and stringent) criteria. The change in HRT-detected progression was assessed by linear regression of sectoral RA/time, defined as slope >1%/year, with significance level tailored according to series variability. Less stringent and stringent criteria were tested. Specificity was estimated by the proportions of control subjects with disease progression and significantly improving subjects (all). Agreement between disc and field progression in the subjects with OHT was assessed with specificities matched for both VF and HRT.
results. Specificity for VF PLR was estimated to be 85.7% to 95.4% when standard criteria were used, and for RA/time to be 88.1% to 90.5% with the less-stringent criteria. In this comparison, 21.2% progressed by RA alone and 20.2% by VF alone, and 12.1% progressed by both RA and VF. Specificity was estimated to be 95.2% to 98.2% for both VF PLR and RA/time, using the three-omitting criteria and the stringent RA/time criteria, respectively. In this comparison, 8.6% progressed by RA alone, 15.1% by VF alone, and 3.5% by both RA and VF.
conclusions. A relatively high frequency of detected disease progression was observed with either method, with progression by VF occurring at least as frequently as progression by RA. Poor agreement between RA and VF progression was observed regardless of the specificity of the progression criteria. The results indicate that, in patients with ocular hypertension, monitoring of both VF and optic disc is necessary, as agreement between optic disc and VF progression is the exception rather than the rule.
The detection of disease progression is of vital importance in the management of patients with an established diagnosis of glaucoma or ocular hypertension (OHT). This is particularly pertinent in view of the results of the Ocular Hypertension Treatment Study (OHTS) and the Early Manifest Glaucoma Trial (EMGT), in which lowering of intraocular pressure (IOP) was found to retard disease progression.
1 2 Glaucoma is characterized by progressive optic neuropathy with associated perimetric deficits. Therefore, assessment of progression has centered on monitoring visual field (VF) changes and structural changes at the optic nerve head (ONH) and the retinal nerve fiber layer (RNFL). Standard automated perimetry (SAP), as performed by the Humphrey Field Analyzer (Carl Zeiss Meditec Inc., Dublin, CA), is a well-established method of VF examination. Devices have been introduced that have the potential to monitor structural changes in the ONH and RNFL over time. These include confocal scanning laser ophthalmoscopy (CSLO), optical coherence tomography (OCT), and scanning laser polarimetry (SLP). CSLO, as performed using the Heidelberg Retina Tomograph (HRT; Heidelberg Engineering, GmbH, Heidelberg, Germany) is the method that has been established the longest. HRT imaging has been shown to be reproducible and to identify structural changes before detection of repeatable VF loss in glaucoma.
3 4 5 6 The latter observation is consistent with the popularly held view that structural damage occurs before functional loss in glaucoma, although the exact nature of the structure–function relationship has yet to be clarified.
7
Several different strategies have been proposed for monitoring VF- and HRT-detected progression. These strategies may be broadly categorized as either event analyses, wherein progression is defined as the surpassing of a predetermined threshold of change, or trend analyses, wherein the behavior of a measurement is assessed over time. The former approach has been particularly useful in defining VF end points in large-scale clinical trials.
8 9 10 Several event analyses have also been described for monitoring HRT-detected rim area (RA) change.
6 11 Trend analyses have a useful advantage over event analyses in clinical practice in that, instead of a binary outcome, a rate of change may be estimated. This is particularly useful at the earliest stages of the disease process and in OHT. A measured rate of progression may assist in the assessment of a patient’s risk of development of functionally significant visual loss and in the decision to commence or alter treatment.
In this study, we compared ONH and VF disease progression in a group of OHT and control subjects observed prospectively as part of a clinical trial. A novel trend analysis of HRT RA progression was compared with established point-wise linear regression (PLR) VF techniques. By assessing agreement of structural and functional methods in subjects with OHT, it is hoped that insight may be gained into the nature of the structure–function relationship at the earliest stages of the glaucomatous process. Secondarily, by assessing method agreement, we examined the feasibility of using a single test (either structural or functional) to monitor progression. For a test to become redundant, an alternative test should provide the investigator with, at a minimum, the same information on progression.
Subjects were selected from a cohort of 255 patients with OHT originally recruited to a betaxolol-versus-placebo study that took place at Moorfields Eye Hospital between 1992 and 1997. Eligibility criteria for this study are described in detail elsewhere.
12 Briefly, OHT was defined as an IOP > 22 and < 35 mm Hg on two or more occasions within a 2-week period, and a baseline mean Advanced Glaucoma Intervention Study (AGIS) VF score of zero (Humphrey Field Analyzer; full-threshold 24-2 program; Carl Zeiss Meditec, Inc.).
8 Subjects had visual acuity at recruitment of 6/12 or better, with no coexistent ocular or neurologic disease.
Control subjects were selected from a cohort of 30 subjects who were recruited among senior citizens and retirees, or were the spouses or friends of subjects in the OHT cohort.
5 These subjects had a baseline IOP < 21 mm Hg and normal findings in a baseline VF test (the same criteria as in the OHT group). Control subjects were excluded if there was a family history of glaucoma or any coexistent ocular or neurologic disease.
The same eye was analyzed in the present study as had originally been randomized in the betaxolol-versus-placebo study. Briefly, randomization was stratified according to risk of conversion to glaucoma, based on pattern electroretinogram testing performed on each subject at recruitment, cup-disc ratio, and IOP.
12 The choice of control eye was based on simple randomization. A subject eye was included in the study if five or more of both VF tests and HRT mean topographies were available for the study period.
Subjects in both groups underwent VF testing at approximately 4-month intervals from the time of recruitment until September 2001. ONH imaging with the HRT was introduced into the protocol in 1994. Imaging initially took place at yearly intervals for the first 2 years of involvement, and subsequently at 4-month intervals until September 2001.
All images and VFs, regardless of quality, were included for analysis, so that a minimum amount of potentially useful data was discarded. The baseline visit was taken as the first visit in which both VF testing and HRT imaging were performed. The study adhered to the tenets of the Declaration of Helsinki and had local ethics committee approval, as well as subjects’ informed consent.
A PLR of each subject’s VF series was performed using PROGRESSOR (Institute of Ophthalmology, London, UK). Two strategies were used to identify progression, one less stringent and the other stringent:
-
Standard criteria: A point is flagged as progressing if it shows a significant negative slope of at least −1 dB/year, with a significance level of
P < 0.01. This is the most commonly used PLR method in published studies.
13 14 15 -
Three-omitting criteria: A point is flagged as progressing if it satisfies the standard criteria in each of three slopes. The first slope is constructed using all time points up to time point
n, the second slope is constructed omitting point
n and including the next point in the series (
n + 1), and the final slope is constructed omitting points
n and
n + 1 with the inclusion of the next point in the series (
n + 2). Increased specificity, compared with the standard criteria, has been demonstrated applying the three-omitting criteria to simulated VF data.
16
VF series were identified as demonstrating significant improvement using the same two strategies, except with a positive slope direction (≥ +1 dB/year).
In the absence of any established independent reference standard for measuring glaucoma progression, the estimated specificity of both tests should be closely matched (or anchored) for the comparison between them to be valid. Two proxy measures were used to estimate specificity: the number of subjects progressing in the control cohort and the number (in both the OHT and control cohorts) demonstrating significant improvement.
Specificity estimates were made for the PLR standard and three-omitting criteria. Two HRT progression strategies (a less stringent and a stringent strategy) were devised by adjustment of the significance levels of the regression analysis, so that the estimated specificities closely matched those of the two PLR VF techniques.
Agreement between VF and RA progression at the end of the study period was assessed in the OHT group, with specificity anchored at the two different levels. Where agreement existed, congruity between the disc and field sectors was assessed with a map designed to compare the anatomic relationship between VF test points in the Humphrey 24-2 test pattern and regions of the ONH
(Fig. 2) .
22
A further comparison between HRT RA progression and VF progression in the OHT group was made using matched numbers of VF and HRT tests, performed on the same day. This process was executed by using only the standard PLR criteria, as sufficient data points may not have been available to perform the confirmatory tests required of the three-omitting criteria. The thinned standard VF progression was compared against the less-stringent HRT criteria.
All statistical analyses were performed on computer (Medcalc, ver. 7.4.2.0; Medcalc Software, Mariakerke, Belgium).
Using the less-stringent criteria (specificity for both tests anchored at approximately 90%), there was agreement between HRT and VF for progression in 24 subjects within the OHT group. A further 42 subjects showed progression by HRT alone compared with 40 by VF alone
(Fig. 3) .
When the stringent criteria were used (specificity anchored at approximately 97%), seven subjects within the OHT cohort showed progression by both HRT and VF. A further 17 subjects showed progression by HRT alone, compared with 30 subjects by VF alone
(Fig. 4) .
Of the 24 subjects with disease progression shown by disc and field with the less-stringent criteria, there was congruity in at least one disc and field sector in 14 (58.3%), compared with 7 (100%) of 7 subjects when the stringent criteria were applied. There was congruity in four sectors in one subject, in two sectors in four subjects, and one sector in eight subjects with the less-stringent criteria. With the less-stringent criteria, congruity was detected in one sector in all seven subjects.
When an equal number of HRT and VF examinations was performed on the same day (i.e., thinned VF data), progression was shown in 22 subjects (11.1%) within the OHT cohort by both HRT and VF. A further 44 subjects (22.2%) showed progression by HRT alone, compared with 25 subjects (12.6%) by VF alone.
An inevitable shortcoming with any study that compares methods of detecting glaucoma progression is the absence of a reference standard method based on which the diagnostic accuracy of the tests used may be defined. The choice of progression criteria is often arbitrary. The relative merits and shortcomings of PLR analysis have been well documented. The adoption of linear regression is supported by modeling of sensitivity/time in series of fields from normal tension glaucoma subjects. A linear model demonstrates an adequate data fit and also generates more accurate prediction of future perimetric change than do higher-order models.
23 PLR using PROGRESSOR may detect progression earlier than STATPAC 2, an event-analysis technique native to the Humphrey Field Analyzer system (Carl Zeiss Meditec, Inc.).
14 However, sensitivity, specificity, and time to detect progression are influenced by the progression criteria selected and, in the absence of an independent reference standard for progression, performance may be judged by data modeling. In such a model, PLR techniques have been shown to have high specificity and to detect progression in more patients but they may require more tests (or time) than event-analysis techniques.
24 However, the longer time required by PLR may, in part, reflect the greater number of patients in whom progression is detected, with patients in whom it is not detected at all, by “event analyses” taking longer to detect by PLR. To achieve satisfactory levels of sensitivity and specificity, PLR requires a minimum of seven or eight VFs.
25 26 This requirement was comfortably exceeded in the majority of subjects in both groups of the present study.
The pattern of RA loss in glaucoma is not yet clearly established. Airaksinen et al.,
27 described three patterns of RA change over time—linear, episodic, and curvilinear—with approximately half of both OHT and glaucoma subjects demonstrating a linear decay. This observation supports the adoption of a linear model to detect HRT RA progression, although linear regression may miss some episodic change, particularly if it occurs in a highly variable series. In addition, it should be appreciated that measurement noise may mimic stepwise and nonlinear change. As with PLR, detection of progression is improved, with a greater amount of data included in the analysis. In this study, there were fewer HRT examinations, compared with VF examinations, in the OHT group, because of less frequent HRT imaging. Some subjects have a particularly high number of VF examinations, as VF conversion was the study end point. These subjects were tested intensively over 3-month periods when VF conversion was suspected, which may introduce some bias favoring the detection of VF progression, as subjects deemed to have converted to glaucoma within the original study have a greater number of VF examinations relative to HRT examinations. This finding has been confirmed by repeating the comparison using a matched number of HRT and VF examinations, which resulted in a much lower detection rate by VF (12.6% compared with 20.2%), although it had very little effect on the level of agreement as regards progression status (11.1% compared to 12.1%). A much higher detection rate of progression by VF was observed in this study compared with previously published reports with similar length of follow-up.
28 29 The higher rate is most likely a reflection of the use of linear regression-based techniques that have been shown to have higher detection rates than event-analysis techniques when sufficient data and length of follow-up are available.
24 In addition, as optic disc appearance was not an entry criterion for the study, there may have been more subjects with OHT in the present study with early glaucomatous damage than there were in the similar studies. High rates of structural progression may be explained by the detection method. Analysis of structural progression in the present study was a quantitative analysis of CSLO images, which has been shown in a primate model of glaucoma to be more sensitive than the subjective evaluation of stereo ONH photographs.
30
The estimation of specificity in this study was derived from proxy measures based on two assumptions. First, significant RA and differential light sensitivity (DLS) improvement over time should not occur. Second, RA and DLS loss at a much greater rate than the age-related estimate should not be observed in control subjects. One may argue that these assumptions are not wholly valid. VF sensitivity may improve because of a learning effect. However, significant learning effects are unlikely in this study because it was required that subjects have reproducibly normal and reliable VFs at baseline.
12 When the topographical change analysis is used to monitor HRT progression, positive topographical changes may be seen when there are also areas of topographic depression.
31 However, isolated improvement is rare. It is uncertain whether such changes exert any sustained influence over the longitudinal RA trend in a given sector. Both RA and VF sensitivity probably decline with ageing. Our rate criteria were set to be higher than average (estimated) rates, but individuals are likely to age at different rates, and so it is possible that some true, age-related, change was detected. Thus, our estimates of specificity may, in fact, constitute an underestimation of true specificity.
The specificity estimates relate to the analysis performed in this study, with progression rates calculated only at the end of the observation period. Were the same criteria applied in the clinical setting, lower specificity would result because the clinician analyzes data for progression at each patient visit, rather than at the end of a specified period. The result is reduced specificity from multiple testing.
In this study, there was poor agreement between ONH progression and VF progression in subjects with OHT, regardless of the specificity of the progression criteria applied. A similar result was reported in a group of subjects with established glaucomatous VF loss followed longitudinally.
32 In that study, event- and trend-based progression analysis methods were assessed by SAP, high-pass resolution perimetry, and HRT. For the trend-based analysis, agreement between all three tests was observed in 2.4% to 7.1% of subjects, depending on the stringency of the criteria. This closely matches the results of the present study, with agreement for progression of 3.5% to 10.6%. The results of these two studies suggest that poor agreement is seen regardless of the stage of disease and criteria for monitoring progression. One may therefore conclude that, as both VF and HRT testing provide additive information on progression, the two cannot be used interchangeably. Therefore, a single test, either of structure or of function, is not yet sufficient for monitoring glaucoma progression in isolation.
Structural damage and loss of visual function are both features of glaucoma. There is a popularly held view that structural changes are detectable before functional changes in progressive glaucoma by using currently available techniques.
7 Some structural changes may occur without concomitant changes in function. This theory was expounded by Fuchs as far back as 1916,
33 and has been supported more recently by descriptions of lamina bowing and astrocytic remodeling in studies of experimental glaucoma.
34 35 Another possibility is that functional loss may occur without concomitant structural alteration; electrophysiological evidence of IOP-mediated ganglion cell dysfunction in the primate retina has recently been described.
36 An explanation for the high frequency of detected VF progression in the present study, in the absence of concomitant identifiable structural progression in many eyes, is that a functional reserve may have been expended before the time of entering into the study. This may be pertinent, as the appearance of the ONH was not taken into account at the time of recruitment. However, this theory is not supported by the results of Artes and Chauhan,
32 who observed a similarly poor level of agreement in subjects with established glaucoma. A recent study, also at odds with the view that structural damage precedes function damage, has demonstrated evidence of electrophysiological changes detectable before structural changes in subjects with OHT.
37
A likely explanation for the apparent structure–function dissociation lies in measurement variability. Even if disc and VF progression rates were identical, differences in measurement noise between the two testing modalities may result in progression’s being detected by one modality, but not the other.
Steps taken to tailor the HRT progression criteria according to RA variability reduce the effect of differing image qualities and measurement noise on false-positive progression detection. Such a reduction has not been possible for the VF analysis, primarily because there is no satisfactory metric with which to measure visual field reliability.
38 39 The issue of visual field variability over time is a complex one, particularly as variability increases in areas of established depressed sensitivity,
40 41 and is beyond the scope of the present study.
It is possible that improved agreement may be observed with further refinement of imaging and visual function tests and data analysis techniques. Machine learning classifiers, both supervised and unsupervised, may be useful in detecting true progression from measurement noise.
42 43 Monitoring topographic changes with a recently described technique, statistic image mapping, may be more useful than monitoring stereometric parameters (such as RA).
44 The adoption of VF spatial filtering techniques may also ameliorate our ability to discriminate perimetric progression.
45 However, until these developments are fully tested and validated, the results of our study indicate that both structural and functional tests should be monitored to identify progression in patients with OHT.
Supported by a Friends of Moorfields Research Fellowship and an unrestricted grant from Heidelberg Engineering.
Submitted for publication December 13, 2005; revised March 1, 2006; accepted May 15, 2006.
Disclosure:
N.G. Strouthidis, Heidelberg Engineering, GmbH (F);
A. Scott, None;
N.M. Peter, None;
D.F. Garway-Heath, Heidelberg Engineering, GmbH (F), Carl Zeiss Meditec, Inc. (C, F)
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be marked “
advertisement” in accordance with 18 U.S.C. §1734 solely to indicate this fact.
Corresponding author: David F. Garway-Heath, Glaucoma Research Unit, Moorfields Eye Hospital, 162 City Road, London EC1V 2PD, UK;
[email protected].
Table 1. Demographic Details of OHT and Control Subjects
Table 1. Demographic Details of OHT and Control Subjects
| OHT | CONTROL |
Subjects (n) | 198 | 21 |
Age (y) | 60 (32–79) | 65 (41–77) |
Follow-up (y) | 6.0 (2.3–7.2) | 5.3 (3.1–6.8) |
HRT examinations (n) | 10 (5–16) | 9 (8–11) |
Visual field examinations (n) | 17 (5–33) | 9 (7–14) |
Baseline mean defect (dB) | +0.1 (+3.0–2.7) | +0.1 (+2.6–2.4) |
Baseline global rim area (mm2) | 1.24 (0.63–2.31) | 1.35 (0.86–2.51) |
Image quality throughout study (MPHSD) | 20 (7–186) | 23 (9–80) |
Table 2. Estimation of Specificity for Visual Field Point-Wise Linear Regression for Both Standard and Three-Omitting Criteria
Table 2. Estimation of Specificity for Visual Field Point-Wise Linear Regression for Both Standard and Three-Omitting Criteria
| Standard Criteria | Three-Omitting Criteria |
No significant improvement | 209/219 = 95.4% | 215/219 = 98.2% |
95% CI | 91.8%–97.5% | 95.4%–99.3% |
No progression in control cohort | 18/21 = 85.7% | 20/21 = 95.2% |
95% CI | 65.4%–95.0% | 77.3%–99.2% |
Specificity estimate | 85.7%–95.4% | 95.2%–98.2% |
Table 3. The Estimation of Specificity for Two Different HRT Progression Techniques
Table 3. The Estimation of Specificity for Two Different HRT Progression Techniques
| Less Stringent* | Stringent, † |
No significant improvement | 193/219 = 88.1% | 215/219 = 98.2% |
95% CI | 83.2%–91.8% | 95.4%–99.3% |
No progression in control cohort | 19/21 = 90.5% | 20/21 = 95.2% |
95% CI | 71.1%–97.4% | 77.3%–99.2% |
Specificity estimates | 88.1%–90.5% | 95.2%–98.2% |
The authors thank Tuan Ho for editing the manuscript.
HigginbothamEJ, GordonMO, BeiserJA, et al. The Ocular Hypertension Treatment Study: topical medication delays or prevents primary open-angle glaucoma in African American individuals. Arch Ophthalmol. 2004;122:813–820.
[CrossRef] [PubMed]HeijlA, LeskeMC, BengtssonB, HymanL, HusseinM. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120:1268–1279.
[CrossRef] [PubMed]TanJC, Garway-HeathDF, HitchingsRA. Variability across the optic nerve head in scanning laser tomography. Br J Ophthalmol. 2003;87:557–559.
[CrossRef] [PubMed]StrouthidisNG, WhiteET, HoTA, HammondCJ, Garway-HeathDF. Factors affecting the test-retest variability of the Heidelberg Retina Tomograph and Heidelberg Retina Tomograph-II. Br J Ophthalmol. 2005;89:1427–1432.
[CrossRef] [PubMed]KamalDS, ViswanathanAC, Garway-HeathDF, HitchingsRA, PoinoosawmyD, BunceC. Detection of optic disc change with the Heidelberg retina tomograph before confirmed visual field change in ocular hypertensives converting to early glaucoma. Br J Ophthalmol. 1999;83:290–294.
[CrossRef] [PubMed]KamalDS, Garway-HeathDF, HitchingsRA, FitzkeFW. Use of sequential Heidelberg retina tomograph images to identify changes at the optic disc in ocular hypertensive patients at risk of developing glaucoma. Br J Ophthalmol. 2000;84:993–998.
[CrossRef] [PubMed]JohnsonC, CioffiG, LiebmannJ, SampleP, ZangwillL, WeinrebR. The relationship between structural and functional alterations in glaucoma: a review. Semin Ophthalmol. 2000;15:221–233.
[CrossRef] [PubMed]Advanced Glaucoma Intervention Study. 2. Visual field test scoring and reliability. Ophthalmology. 1994;101:1445–1455.
[CrossRef] [PubMed]MuschDC, LichterPR, GuireKE, StandardiCL. The Collaborative Initial Glaucoma Treatment Study: study design, methods, and baseline characteristics of enrolled patients. Ophthalmology. 1999;106:653–662.
[CrossRef] [PubMed]HeijlA, LeskeMC, BengtssonB, HusseinM. Measuring visual field progression in the Early Manifest Glaucoma Trial. Acta Ophthalmol Scand. 2003;81:286–293.
[CrossRef] [PubMed]TanJC, HitchingsRA. Approach for identifying glaucomatous optic nerve progression by scanning laser tomography. Invest Ophthalmol Vis Sci. 2003;44:2621–2626.
[CrossRef] [PubMed]KamalD, Garway-HeathD, RubenS, et al. Results of the betaxolol versus placebo treatment trial in ocular hypertension. Graefes Arch Clin Exp Ophthalmol. 2003;241:196–203.
[CrossRef] [PubMed]McNaughtAI, CrabbDP, FitzkeFW, HitchingsRA. Visual field progression: comparison of Humphrey Statpac2 and pointwise linear regression analysis. Graefes Arch Clin Exp Ophthalmol. 1996;234:411–418.
[CrossRef] [PubMed]ViswanathanAC, FitzkeFW, HitchingsRA. Early detection of visual field progression in glaucoma: a comparison of PROGRESSOR and STATPAC 2. Br J Ophthalmol. 1997;81:1037–1042.
[CrossRef] [PubMed]Nouri-MahdaviK, CaprioliJ, ColemanAL, HoffmanD, GaasterlandD. Pointwise linear regression for evaluation of visual field outcomes and comparison with the advanced glaucoma intervention study methods. Arch Ophthalmol. 2005;123:193–199.
[CrossRef] [PubMed]GardinerSK, CrabbDP. Examination of different point-wise linear regression methods for determining visual field progression. Invest Ophthalmol Vis Sci. 2002;43:1400–1407.
[PubMed]StrouthidisNG, WhiteET, OwenVM, HoTA, Garway-HeathDF. Improving the repeatability of Heidelberg retina tomograph and Heidelberg retina tomograph II rim area measurements. Br J Ophthalmol. 2005;89:1433–1437.
[CrossRef] [PubMed]TanJC, Garway-HeathDF, FitzkeFW, HitchingsRA. Reasons for rim area variability in scanning laser tomography. Invest Ophthalmol Vis Sci. 2003;44:1126–1131.
[CrossRef] [PubMed]AltmanDG. Statistics and ethics in medical research. VI. Presentation of results. BMJ. 1980;281:1542–1544.
[CrossRef] [PubMed]JohnsonBM, MiaoM, SadunAA. Age-related decline of human optic nerve axon populations. Age. 1987;10:5–9.
[CrossRef] Garway-HeathDF, WollsteinG, HitchingsRA. Aging changes of the optic nerve head in relation to open angle glaucoma. Br J Ophthalmol. 1997;81:840–845.
[CrossRef] [PubMed]Garway-HeathDF, PoinoosawmyD, FitzkeFW, HitchingsRA. Mapping the visual field to the optic disc in normal tension glaucoma eyes. Ophthalmology. 2000;107:1809–1815.
[CrossRef] [PubMed]McNaughtAI, CrabbDP, FitzkeFW, HitchingsRA. Modelling series of visual fields to detect progression in normal-tension glaucoma. Graefes Arch Clin Exp Ophthalmol. 1995;233:750–755.
[CrossRef] [PubMed]VestiE, JohnsonCA, ChauhanBC. Comparison of different methods for detecting glaucomatous visual field progression. Invest Ophthalmol Vis Sci. 2003;44:3873–3879.
[CrossRef] [PubMed]KatzJ, GilbertD, QuigleyHA, SommerA. Estimating progression of visual field loss in glaucoma. Ophthalmology. 1997;104:1017–1025.
[CrossRef] [PubMed]SpryPG, BatesAB, JohnsonCA, ChauhanBC. Simulation of longitudinal threshold visual field data. Invest Ophthalmol Vis Sci. 2000;41:2192–2200.
[PubMed]AiraksinenPJ, TuulonenA, AlankoHI. Rate and pattern of neuroretinal rim area decrease in ocular hypertension and glaucoma. Arch Ophthalmol. 1992;110:206–210.
[CrossRef] [PubMed]GordonMO, BeiserJA, BrandtJD, et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:714–720.; discussion 829–830
[CrossRef] [PubMed]MigliorS, ZeyenT, PfeifferN, Cunha-VazJ, TorriV, AdamsonsI. Results of the European Glaucoma Prevention Study. Ophthalmology. 2005;112:366–375.
[CrossRef] [PubMed]ErvinJC, LemijHG, MillsRP, QuigleyHA, ThompsonHW, BurgoyneCF. Clinician change detection viewing longitudinal stereophotographs compared to confocal scanning laser tomography in the LSU Experimental Glaucoma (LEG) Study. Ophthalmology. 2002;109:467–481.
[CrossRef] [PubMed]ChauhanBC, BlanchardJW, HamiltonDC, LeBlancRP. Technique for detecting serial topographic changes in the optic disc and peripapillary retina using scanning laser tomography. Invest Ophthalmol Vis Sci. 2000;41:775–782.
[PubMed]ArtesPH, ChauhanBC. Longitudinal changes in the visual field and optic disc in glaucoma. Prog Retin Eye Res. 2005;24:333–354.
[CrossRef] [PubMed]FuchsE. Uer die lamina cribrosa. Albrecht von Graefes Arch Ophthalmol. 1916;91:435–485.
[CrossRef] HayrehSS, Pe’erJ, ZimmermanMB. Morphologic changes in chronic high-pressure experimental glaucoma in rhesus monkeys. J Glaucoma. 1999;8:56–71.
[PubMed]HernandezMR, PenaJD, SelvidgeJA, Salvador-SilvaM, YangP. Hydrostatic pressure stimulates synthesis of elastin in cultured optic nerve head astrocytes. Glia. 2000;32:122–136.
[CrossRef] [PubMed]WeberAJ, HarmanCD. Structure-function relations of parasol cells in the normal and glaucomatous primate retina. Invest Ophthalmol Vis Sci. 2005;46:3197–3207.
[CrossRef] [PubMed]ParisiV, MigliorS, ManniG, CentofaniM, BucciMG. Clinical ability of pattern electroretinograms and visual evoked potentials in detecting visual dysfunction in ocular hypertension and glaucoma. Ophthalmology. 2006;113:216–228.
[CrossRef] [PubMed]HensonDB, ChaudryS, ArtesPH, FaragherEB, AnsonsA. Response variability in the visual field: comparison of optic neuritis, glaucoma, ocular hypertension, and normal eyes. Invest Ophthalmol Vis Sci. 2000;41:417–421.
[PubMed]BengtssonB. Reliability of computerized perimetric threshold tests as assessed by reliability indices and threshold reproducibility in patients with suspect and manifest glaucoma. Acta Ophthalmol Scand. 2000;78:519–522.
[CrossRef] [PubMed]HeijlA, LindgrenA, LindgrenG. Test-retest variability in glaucomatous visual fields. Am J Ophthalmol. 1989;108:130–135.
[CrossRef] [PubMed]ChauhanBC, TompkinsJD, LeBlancRP, McCormickTA. Characteristics of frequency-of-seeing curves in normal subjects, patients with suspected glaucoma, and patients with glaucoma. Invest Ophthalmol Vis Sci. 1993;34:3534–3540.
[PubMed]SamplePA, BodenC, ZhangZ, et al. Unsupervised machine learning with independent component analysis to identify areas of progression in glaucomatous visual fields. Invest Ophthalmol Vis Sci. 2005;46:3684–3692.
[CrossRef] [PubMed]TuckerA, VinciottiV, LiuX, Garway-HeathD. A spatio-temporal Bayesian network classifier for understanding visual field deterioration. Artif Intell Med. 2005;34:163–177.
[CrossRef] [PubMed]PattersonAJ, Garway-HeathDF, StrouthidisNG, CrabbDP. A new statistical approach for quantifying change in series of retinal and optic nerve head topography images. Invest Ophthalmol Vis Sci. 2005;46:1659–1667.
[CrossRef] [PubMed]GardinerSK, CrabbDP, FitzkeFW, HitchingsRA. Reducing noise in suspected glaucomatous visual fields by using a new spatial filter. Vision Res. 2004;44:839–848.
[CrossRef] [PubMed]